Abstract. Renal coloboma syndrome is an autosomal dominant condition characterized by renal lesions and optic nerve abnormalities. We report an 11-yr-old Japanese girl with familial renal coloboma syndrome, who also had Graves' disease. Four affected family members had a previously reported heterozygous mutation (c.76dupG, p.Val26Glyfs*28) in the PAX2 gene. We hypothesized that PAX2 mutations may increase the risk of autoimmune diseases through alterations of human β-defensin 1 expression.
Introduction
Renal coloboma syndrome (OMIM #120330) is an autosomal dominant condition characterized by renal lesions and optic nerve abnormalities (1) . Renal manifestations include renal hypoplasia, enuresis due to urinary concentrating defect, multicystic dysplastic kidney, and renal insufficiency. Ocular manifestations include optic nerve dysplasia, scleral staphyloma, optic nerve cyst and retinal detachment. More than 170 affected individuals and 80 families have been reported to date (2).
PAX2 is the only gene known to cause renal coloboma syndrome. Genotype-phenotype correlation is not evident among PAX2 mutation carriers. Optic nerve abnormalities and renal lesions are variably manifested by patients with PAX2 mutations, even within the same family (2, 3). While several nonrenal or nonophthalmological features, such as hearing impairment, central nervous system anomalies, developmental delay, cardiac defects, abnormality of the hand, and ligamentous laxity, have been reported (4), there is no report documenting autoimmune diseases or thyroid diseases.
Here, we report a patient with Graves' disease and a familial PAX2 mutation, and discuss the potential relationship between Graves' disease and PAX2 mutations.
Case Report
Family pedigree is shown in Fig. 1A . Clinical information of the family members is summarized in Table 1 . We describe clinical pictures of three affected family members.
III-4
The proband is an 11-yr-old girl. She is the second child of non-consanguineous Japanese parents. Serial prenatal ultrasound examinations showed no renal anomalies, although oligohydramnios was noted. She was delivered vaginally at 39 wk of gestation. Her birth weight was 2,752 g (−0.6 SD), length was, 47.5 cm (−0.6 SD), and head circumference was, 31.0 cm (−1.6 SD).
At 4 mo of age, internal strabismus and horizontal nystagmus were noticed, and she was referred to our hospital. Ocular fundus examination showed bilateral optic nerve dysplasia ( Fig. 2A, B was not performed. She was referred to the pediatric endocrinology division at 10 yr of age because of weight loss. On examination, hand tremor and tachycardia (139 bpm) were apparent. Her thyroid was soft and large by palpation. She also had exophthalmos. Blood tests revealed marked hyperthyroidism with a suppressed thyroidstimulating hormone level (<0.01 µIU/L, reference 0.5-5) and elevated free triiodothyronine (>32.55 pg/mL, reference 2.3-4.0) and free thyroxine levels (>7.77 ng/dL, reference 0.90-1.70). Ultrasonography revealed an enlarged thyroid (estimated size, >34.4 mL, reference 2.9-6.3 (5, 6)), which had heterogeneously low echogenicity. Marked hypervascularity was shown by color Doppler imaging (Fig. 3) . The diagnosis of Graves' disease was confirmed by elevated anti-thyroid stimulating hormone receptor antibody (102 IU/L, reference <1.0). Treatment with 30 mg of thiamazole and 1 mL of 2.5% aqueous iodine solution improved clinical symptoms within a month. Then, her anti-thyroid stimulating hormone receptor antibody titers were found to be reduced. Her serum thyroid-stimulating hormone levels had been suppressed. She needed 15 mg of thiamazole two years after diagnosis (Fig. 4) .
She has suffered from bronchial asthma with a high immunoglobulin E (IgE) level (511 IU/mL, reference <173) for five years. Her bronchial asthma has been well controlled with montelukast and inhaled beclomethasone. Other immunological tests, including serum levels of immunoglobulins (IgG, IgA, IgM) and blastoid transformation of lymphocytes in response to concanavalin-A and phytohemagglutinin, were within normal limits.
II-3
The proband's uncle is 43 yr old. A periodic medical examination at school revealed proteinuria at 10 yr of age. He presented with enuresis until 11 yr of age. The results of renal (Fig. 2C, D) . At 42 yr of age, retinal detachment of his left eye occurred.
II-4
The proband's mother is 37 yr old. She presented with enuresis until 12 yr old. At 12 yr of age, a periodic medical examination at school revealed proteinuria for the first time. Ultrasonography revealed bilateral renal hypoplasia. At 14 yr of age, left renal biopsy revealed no specific findings. At 26 yr of age, she became pregnant with the proband (III-4) , and her renal function became worse. Repeated renal biopsy revealed no specific findings (Fig.  2E) . When she became pregnant with a fetus (III-6) at 32 yr of age, her renal function further deteriorated and hypertension developed. The family elected to interrupt the pregnancy at 10 wk of gestation. She was obese, and her body mass index was 32.8 at her last visit.
Mutation analysis of the PAX2 gene
After obtaining written informed consent, we extracted genomic DNA from peripheral blood samples or nails of four family members (II-3, II-4, III-4 and III-7) using standard protocols. Genomic DNA samples were PCR-amplified for the coding 11 exons and their splice sites of the PAX2 gene (7), and the PCR products were subjected to direct sequencing from both directions on an autosequencer. All of them had a heterozygous mutation (c.76dupG, p.Val26Glyfs*28) that inserts an extra guanine nucleotide in a stretch of seven guanine nucleotides (Fig. 1B) .
Discussion
We described a Japanese family with renal coloboma syndrome and a heterozygous mutation (c.76dupG, p.Val26Glyfs*28) in exon 2 of the PAX2 gene. Clinical manifestations varied within the family. Ocular fundus manifestations included normal fundus, optic nerve dysplasia, and retinal detachment. Renal manifestations included renal hypoplasia, urinary concentrating defects, proteinuria and end-stage renal insufficiency. One of the two patients with renal failure had a kidney transplant.
The c.76dupG mutation is one of the most frequent PAX2 mutations (8) . It is predicted to have a premature termination codon located in 54-56 nucleotides upstream of the subsequent exon-intron junction. The c.76dupG mutation may trigger nonsense-mediated decay (NMD), although whether the mutation triggers NMD remains to be clarified. Even if the mutant RNA is not destroyed by NMD, the c.76dupG mutation would lead to a truncated protein lacking any functional domains. Clinical presentation of the c.76dupG carriers is known to be highly variable between individuals and even within a family (3, 7) . Genotype-phenotype correlation is not evident among PAX2 mutation carriers. It has been hypothesized that genetic, epigenetic or environmental factors may modulate the clinical manifestations in humans and mice with PAX2 mutations (9, 10) . Interestingly, the proband had an atypical complication, Graves' disease. Graves' disease is an autoimmune disorder mediated by agonistic antibodies to the thyroid stimulating hormone receptor, which is the commonest cause of hyperthyroidism in childhood and adolescence. PAX2 mutations or renal coloboma syndrome associated with Graves' disease has not been reported so far. One previous study showed that the increased risk of Henoch-Schönlein purpura nephritis, a putative immune-mediated glomerular disease, was associated with PAX2 gene polymorphisms (11) . Although coexistence of renal coloboma syndrome and Graves' disease in the proband could be only coincidental, we think it probable that PAX2 mutations may be associated with development of Graves' disease. PAX2 has been known to be expressed in a subset of lymphocytes (12) , and thus would have a physiological role in the immune system. PAX2 represses human β-defensin 1 expression through binding to the promoter (13) . Functional single nucleotide polymorphisms of β-defensin 1 were reported to be risk factors for development of systemic lupus erythematosus (14) and autoimmune thyroid diseases in type 1 diabetes patients (15) . We speculate that PAX2 mutations may increase the risk of autoimmune diseases, including Graves' disease, through alterations of human β-defensin 1 expression.
In summary, we reported a patient with a familial PAX2 mutation, who also had Graves' disease. Further study will clarify whether PAX2 mutations can be a risk factor for development of autoimmune diseases.
